Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

PHASE1,PHASE2

Phase

COMPLETED

Status

744

Enrollment

INDUSTRY

Sponsor class

Conditions

BIOLOGICAL: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
BIOLOGICAL: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
BIOLOGICAL: Two doses of placebo at the emergency vaccination schedule
BIOLOGICAL: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
BIOLOGICAL: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
BIOLOGICAL: Two doses of placebo at the routine vaccination schedule
BIOLOGICAL: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
BIOLOGICAL: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
BIOLOGICAL: Three doses of placebo at the emergency vaccination schedule
BIOLOGICAL: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
BIOLOGICAL: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
BIOLOGICAL: Three doses of placebo at the routine vaccination schedule

Sinovac Research and Development Co., Ltd.